Search Result

Results for "

lupus

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AIM2 (1) Amino Acid Derivatives (1) Amyloid-β (1) Apoptosis (3) Autophagy (5) Bcl-2 Family (1) Btk (3) Cathepsin (1) CD28 (1) Cytochrome P450 (1) Glucocorticoid Receptor (2) Histone Methyltransferase (2) IFNAR (1) Interleukin Related (1) IRAK (2) JAK (4) Mitochondrial Metabolism (1) NF-κB (1) NOD-like Receptor (NLR) (2) Parasite (5) Phosphodiesterase (PDE) (2) Potassium Channel (4) Protein Arginine Deiminase (3) ROS Kinase (2) SARS-CoV (3) TGF-beta/Smad (1) TNF Receptor (5) Toll-like Receptor (TLR) (8)
By Research Areas:	Cancer (13) Endocrinology (2) Infection (5) Inflammation/Immunology (54) Metabolic Disease (4)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W031727

Hydroxychloroquine Maximum Cited Publications 49 Publications Verification	Parasite Toll-like Receptor (TLR) SARS-CoV Autophagy	Infection Cancer
Hydroxychloroquine (HCQ) is a synthetic oral antimalarial drug that can be used in the study of malaria and autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. Hydroxychloroquine is a potent autophagic flux inhibitor with antiviral activity (such as SARS-CoV-2 virus) that inhibits Toll-like receptor 7/9 (TLR7/9) signaling .

HY-B0214

Prednisone 5+ Cited Publications Dehydrocortisone	Glucocorticoid Receptor Apoptosis	Inflammation/Immunology Endocrinology Cancer
Prednisone (Adasone) is a corticosteroid agent with anti-inflammatory and immunosuppressive effects that can be used to study diseases related to systemic lupus erythematosus .

HY-153460

TLR7/8/9 antagonist 2	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7/8/9 antagonist 2 is an orally active TLR7/8/9 antagonist. TLR7/8/9 antagonist 2 has inhibitory activities for HEK/hTLR7, HEK/hTLR8 and HEK/hTLR9 with IC₅₀ values of 0.011 μM, 0.029 μM and 0,052 μM, respectively.TLR7/8/9 antagonist 2 has high bioavailability in vivo.TLR7/8/9 antagonist 2 can be used for the research of auto-inflammatory diseases such as systemic lupus erythematosus or lupus nephritis .

HY-137553A

β-Aminoarteether maleate SM934	NOD-like Receptor (NLR)	Inflammation/Immunology
β-Aminoarteether maleate (SM934) is an Artemisinin derivative with orally active. β-Aminoarteether maleate can be used for inflammation and autoimmune disease research, such as lupus diseases .

HY-137553

β-Aminoarteether SM934 free base	NOD-like Receptor (NLR)	Inflammation/Immunology
β-Aminoarteether (SM934 free base) is an Artemisinin derivative with orally active. β-Aminoarteether can be used for inflammation and autoimmune disease research, such as lupus diseases .

HY-P99316

Sirukumab CNTO-136	Interleukin Related	Inflammation/Immunology
Sirukumab (CNTO-136) is a human monoclonal anti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab has the potential for active lupus nephritis research .

HY-P99482

Blisibimod A 623; AMG 623	TNF Receptor	Inflammation/Immunology
Blisibimod (A 623) is a potent and selective tetravalent inhibitor of B-cell activating factor (BAFF). Blisibimod can be used for the research of systemic lupus erythematosus (SLE) .

HY-147264

Edecesertib GS-5718	IRAK	Inflammation/Immunology
Edecesertib (GS-5718) is a selective, potent, orally active IRAK-4 inhibitor. Edecesertib has anti-inflammatory activity. Edecesertib can be used for rheumatoid arthritis (RA) and lupus erythematosus (LE) research .

HY-P99315

Ruplizumab BG 9588; Anti-Human CD40L Recombinant Antibody	TNF Receptor	Inflammation/Immunology
Ruplizumab (BG 9588) is a humanized monoclonal anti-CD40L (TNF Receptor) IgG1κ antibody. Ruplizumab has the potential for systemic lupus erythematosus disease research .

HY-U00318

JAK-IN-11	JAK	Inflammation/Immunology
JAK-IN-11 is a potent and selective JAK inhibitor extracted from patent WO2012122452A1, Compound II, has the potential for the skin disorders (such as cutaneous lupus) treatment . JAK-IN-11 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-15374

Frentizole	Amyloid-β	Inflammation/Immunology
Frentizole, an FDA-approved immunosuppressant, is a Aβ-ABAD (binding alcohol dehydrogenase) interaction inhibitor with an IC₅₀ value of 200 μM. Frentizole is used in studies of diseases related to rheumatoid arthritis and systemic lupus erythematosus .

HY-145588

Povorcitinib INCB54707	JAK	Inflammation/Immunology
Povorcitinib (INCB54707) is a potent and selective JAK1 inhibitor that effectively reduces abscesses and inflammatory nodules. Povorcitinib is used to study cutaneous lupus erythematosus (CLE) and lichen planus (LP) (information extracted from patent WO2021076124A1).

HY-145588A

Povorcitinib phosphate INCB54707 phosphate	JAK	Inflammation/Immunology
Povorcitinib (INCB54707) phosphate is a potent and selective JAK1 inhibitor that effectively reduces abscesses and inflammatory nodules. Povorcitinib phosphate can be used to study cutaneous lupus erythematosus (CLE) and lichen planus (LP) (information extracted from patent WO2021076124A1).

HY-P99219

Sifalimumab MEDI-545; MDX 1103	IFNAR	Inflammation/Immunology
Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research .

HY-109143B

(R)-Elsubrutinib (R)-ABBV-105	Btk	Inflammation/Immunology Cancer
(R)-Elsubrutinib ((R)-ABBV-105) is a Btk inhibitor. (R)-Elsubrutinib can be used in studies of immune diseases (such as rheumatoid arthritis, psoriasis, ankylosing spondylitis, asthma, systemic lupus erythematosus) and cancer .

HY-P9952

Belimumab 2 Publications Verification LymphoStat B	TNF Receptor	Inflammation/Immunology
Belimumab (LymphoStat B) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF). Belimumab can be used for systemic lupus erythematosus (SLE) research .

HY-153254

BMS905	Toll-like Receptor (TLR)	Inflammation/Immunology
BMS905 is an orally active TLR7 and TLR8 dual inhibitor (IC₅₀s: 0.7 and 3.2 nM respectively). BMS905 inhibits TLR7 or TLR8 induced IL-6 production in human/mouse whole blood. BMS905 can be used for research of lupus .

HY-136093B

Lixumistat IM156 free base; HL156A free base; HL271 free base	Mitochondrial Metabolism	Cancer
Lixumistat (IM156) is a novel biguanide mitochondrial protein complex 1 inhibitor of oxidative phosphorylation (OXPHOS) with anti-tumor activity. Lixumistat regulates OXPHOS to attenuate mitochondrial metabolic reprogramming and inhibit lung fibrosis. Lixumistat also suppresses B-cell activation to alleviate systemic lupus erythematosus .

HY-144619

TLR7/8 antagonist 2	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7/8 antagonist 2 (Compound 15) is a potent and orally active agonist of TLR7/8 with IC₅₀s of 4.9 and 0.6 nM, respectively. Inappropriate activation of TLR7 and TLR8 is linked to several autoimmune diseases, such as lupus erythematosus. TLR7/8 antagonist 2 has the potential for the research of autoimmune diseases .

HY-18620

DZ2002 1 Publications Verification	Others	Inflammation/Immunology
DZ2002 is an orally active, reversible and low-cytotoxic type III SAHH inhibitor (K_i=17.9 nM), with good immunosuppressive activity. DZ2002 prevents the development of experimental dermal fibrosis by reversing the profibrotic phenotype of various cell types. DZ2002 can be used in studies of autoimmune diseases such as lupus syndrome and systemic sclerosis .

HY-P3560

Edratide TV 4710	Apoptosis	Inflammation/Immunology
Edratide (TV 4710) is a synthetic peptide of 19 amino acid based on the complementarity-determining region 1 (CDR1) of a human anti-DNA antibody that expresses a major idiotype denoted 16/6 Id. Edratide reduces the rates of apoptosis (Apoptosis) and down-regulates of caspase-8 and caspase-3, up-regulates Bcl-xL. Edratide has the potential for the research of systemic lupus erythematosus (SLE) .

HY-148411

Abetimus LJP 394 free base	Others	Inflammation/Immunology
Abetimus (LJP 394 free base) is an immunosuppressant consisting of four double-stranded DNA (dsDNA) oligonucleotides. Abetimus is capable of crosslinking anti-dsDNA antibodies on the surface of B cells, and decreases anti-dsDNA antibodies levels. Abetimus has the potential for research of systemic lupus erythematosus .

HY-P99220

Tabalumab LY2127399	TNF Receptor	Inflammation/Immunology
Tabalumab (LY2127399) is a human anti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus .

HY-P3507

Dalazatide ShK-186	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-P3507A

Dalazatide TFA ShK-186 TFA	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-150751

ODN TTAGGG ODN A151	Toll-like Receptor (TLR) AIM2	Inflammation/Immunology
ODN TTAGGG (A151), inhibitory oligonucleotide (ODN), is a TLR9, AIM2 and cGAS antagonist. ODN TTAGGG is immunosuppressive and inhibits AIM2 inflammasome activation, as well as cGAS activation, by competing with DNA. ODN TTAGGG can be used in the study of lupus erythematosus and other related autoimmune diseases. ODN TTAGGG sequence: 5'-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-3' .

HY-W109513

Boc-Lys(Z)-OH (DCHA)	Amino Acid Derivatives	Inflammation/Immunology
Boc-Lys(Z)-OH (DCHA) is a involves in synthesis thymosin β4, βg and β6 fragments, and increases E-rosette forming capacity in Lupus Nephritis model. Boc-Lys(Z)-OH (DCHA) involves in synthesis Boc-Lyz-OCH3 and acts as a reagent of peptidyl thrombin inhibitors production .

HY-105037

Forigerimod IPP-201101	Autophagy	Inflammation/Immunology
Forigerimod (IPP-201101) is a CD4 T-cell modulator. Forigerimod is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) .

HY-105037A

Forigerimod TFA IPP-201101 TFA	Autophagy	Inflammation/Immunology
Forigerimod TFA (IPP-201101 TFA) is a CD4 T-cell modulator. Forigerimod TFA is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod TFA can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) .

HY-131968

BMS-986202	JAK Cytochrome P450	Inflammation/Immunology
BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC₅₀ value of 0.19 nM and a K_i of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC₅₀ value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium .

HY-P99325

Toralizumab IDEC-131; Anti-Human CD40 ligand Recombinant Antibody	TNF Receptor	Inflammation/Immunology
Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab, a immunosuppressive agent, has the potential for active systemic lupus erythematosus (SLE) research .

HY-135304

PAD-IN-2	Protein Arginine Deiminase	Inflammation/Immunology Cancer
PAD-IN-2 is a potent pad4 inhibitor (IC₅₀: <1 μM). PAD-IN-2 can be used in the research of auto-immune diseases and cancers, such as rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cystic fibrosis, asthma, multiple sclerosis and psoriasis .

HY-125099

AFM-30a	Protein Arginine Deiminase	Inflammation/Immunology Cancer
AFM-30a is a potent protein arginine deiminase 2 (PAD2) inhibitor and has excellent PAD2-selectivity. AFM-30a binds to PAD2 with an EC₅₀ value of 9.5 μM. AFM-30a also inhibits H3 citrullination with an EC₅₀ value of 0.4 μM. AFM-30a can be used for the research of certain cancers and a variety of autoimmune diseases including rheumatoid arthritis (RA), multiple sclerosis, lupus, and ulcerative colitis .

HY-125099A

AFM-30a hydrochloride	Protein Arginine Deiminase	Inflammation/Immunology Cancer
AFM-30a hydrochloride is a potent protein arginine deiminase 2 (PAD2) inhibitor and has excellent PAD2-selectivity. AFM-30a hydrochloride binds to PAD2 with an EC₅₀ value of 9.5 μM. AFM-30a hydrochloride also inhibits H3 citrullination with an EC₅₀ value of 0.4 μM. AFM-30a hydrochloride can be used for the research of certain cancers and a variety of autoimmune diseases including rheumatoid arthritis (RA), multiple sclerosis, lupus, and ulcerative colitis .

HY-13108

Bz 423 1 Publications Verification BZ48	Bcl-2 Family	Inflammation/Immunology
Bz 423 is a pro-apoptotic 1,4-benzodiazepine with therapeutic properties in murine models of lupus demonstrating selectivity for autoreactive lymphocytes, and activates Bax and Bak.

HY-P99606

Cirevetmab ZTS-00521426	TGF-beta/Smad	Inflammation/Immunology
Cirevetmab (ZTS-00521426) is an immunoglobulin G2-kappa, Canis lupus familiaris TGFB1 caninized monoclonal antibody. Cirevetmab is an immunomodulator .

HY-B0214R

Prednisone (Standard) Dehydrocortisone (Standard)	Glucocorticoid Receptor Apoptosis	Inflammation/Immunology Endocrinology Cancer
Prednisone (Standard) is the analytical standard of Prednisone. This product is intended for research and analytical applications. Prednisone (Adasone) is a corticosteroid agent with anti-inflammatory and immunosuppressive effects that can be used to study diseases related to systemic lupus erythematosus .

HY-18018

RN486 3 Publications Verification	Btk	Inflammation/Immunology
RN486 is a potent, selective and orally active Btk inhibitor with an IC₅₀ of 4.0 nM and a K_d of 0.31 nM. RN486 is less active for other kinases. RN486 can be used for rheumatoid arthritis and systemic lupus erythematosus research .

HY-N6857

Armepavine	NF-κB	Inflammation/Immunology
Armepavine, an active compound from Nelumbo nucifera, exerts not only anti-inflammatory effects on human peripheral blood mononuclear cells, but also immunosuppressive effects on T lymphocytes and on lupus nephritic mice. Armepavine inhibits TNF-α-induced MAPK and NF-κB signaling cascades .

HY-17437A

Mefloquine hydrochloride 2 Publications Verification Mefloquin hydrochloride	Parasite SARS-CoV Autophagy Potassium Channel ROS Kinase	Infection Metabolic Disease Inflammation/Immunology Cancer
Mefloquine hydrochloride (Mefloquin hydrochloride), a quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine hydrochloride is also a K ⁺ channel (KvQT1/minK) antagonist with an IC₅₀ of ~1 μM. Mefloquine hydrochloride can be used for malaria, systemic lupus erythematosus and cancer research .

HY-150740

ODN 21595	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 21595 is a Guanine-Modified TLR7 and TLR9 inhibitor. ODN 21595 inhibits the release of IFN-α and IL-6 with no cytotoxic. ODN 21595 reduces the expression of CD86 and HLA-DR. ODN 21595 has the potential for the research of systemic lupus erythematosus (SLE) .

HY-150740A

ODN 21595 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 21595 sodium is a Guanine-Modified TLR7 and TLR9 inhibitor. ODN 21595 sodium inhibits the release of IFN-α and IL-6 with no cytotoxic. ODN 21595 sodium reduces the expression of CD86 and HLA-DR. ODN 21595 sodium has the potential for the research of systemic lupus erythematosus (SLE) .

HY-19836

Zimlovisertib 1 Publications Verification PF-06650833	IRAK	Inflammation/Immunology
Zimlovisertib (PF-06650833) is a potent, selective and orally active inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4) with IC₅₀s of 0.2 and 2.4 nM in the cell and PBMC assay, respectively. Zimlovisertib is used to treat diseases such as rheumatoid arthritis, lupus, and lymphomas .

HY-17437

Mefloquine Mefloquin	Parasite Autophagy SARS-CoV Potassium Channel ROS Kinase	Infection Metabolic Disease Inflammation/Immunology Cancer
Mefloquine (Mefloquin), an orally active and potent quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine is also a K ⁺ channel (KvQT1/minK) antagonist with an IC₅₀ of ~1 μM. Mefloquine can be used for malaria, systemic lupus erythematosus and cancer research .

HY-150095

YE6144	Others	Inflammation/Immunology
YE6144 is a prototypical interferon regulatory factor 5 (IRF5) inhibitor. YE6144 selectively suppresses IRF5 activity through inhibition of IRF5 phosphorylation .

HY-114374

RO5461111	Cathepsin	Inflammation/Immunology
RO5461111 a highly specific and orally active antagonist of Cathepsin S with IC₅₀s of 0.4 nM (human Cathepsin S) and 0.5 nM (murine Cathepsin S), respectively. RO5461111 can effectively inhibit the activation of antigen-specific T cells and B cells. RO5461111 can improve pulmonary inflammation and lupus nephritis .

HY-19834

Fenebrutinib 5+ Cited Publications GDC-0853	Btk	Cancer
Fenebrutinib (GDC-0853) is a potent, selective, orally available, and noncovalent bruton's tyrosine kinase (Btk) inhibitor with K_is of 0.91 nM, 1.6, 1.3, 12.6, and 3.4 nM for WT Btk, and the C481S, C481R, T474I, T474M mutants. Fenebrutinib has the potential for rheumatoid arthritis and systemic lupus erythematosus research .

HY-124603

AT791 2 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology
AT791 is a potent and orally bioavailable TLR7 and TLR9 inhibitor. AT791 inhibits TLR7 and 9 signaling in a variety of human and mouse cell types and inhibits DNA-TLR9 interaction in vitro .

HY-P99717

Lulizumab pegol BMS-931699	CD28	Inflammation/Immunology
Lulizumab pegol (BMS-931699) is an anti-CD28 antibody antagonist. Lulizumab pegol effectively inhibits T-cell proliferation and it can be used for the reseach of kidney transplantation and autoimmunity disease .

HY-147642

ChemR23-IN-4

Others Inflammation/Immunology

ChemR23-IN-4 (Compound 13) is a potent and orally efficacious ChemR23 inhibitor with an IC₅₀ of 17 nM against human ChemR23 .

Cat. No.	Product Name	Target	Research Area

HY-P3560

Edratide TV 4710	Apoptosis	Inflammation/Immunology
Edratide (TV 4710) is a synthetic peptide of 19 amino acid based on the complementarity-determining region 1 (CDR1) of a human anti-DNA antibody that expresses a major idiotype denoted 16/6 Id. Edratide reduces the rates of apoptosis (Apoptosis) and down-regulates of caspase-8 and caspase-3, up-regulates Bcl-xL. Edratide has the potential for the research of systemic lupus erythematosus (SLE) .

HY-P3507A

Dalazatide TFA ShK-186 TFA	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-P3507

Dalazatide ShK-186	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-W109513

Boc-Lys(Z)-OH (DCHA)	Amino Acid Derivatives	Inflammation/Immunology
Boc-Lys(Z)-OH (DCHA) is a involves in synthesis thymosin β4, βg and β6 fragments, and increases E-rosette forming capacity in Lupus Nephritis model. Boc-Lys(Z)-OH (DCHA) involves in synthesis Boc-Lyz-OCH3 and acts as a reagent of peptidyl thrombin inhibitors production .

HY-105037

Forigerimod IPP-201101	Autophagy	Inflammation/Immunology
Forigerimod (IPP-201101) is a CD4 T-cell modulator. Forigerimod is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) .

HY-105037A

Forigerimod TFA IPP-201101 TFA	Autophagy	Inflammation/Immunology
Forigerimod TFA (IPP-201101 TFA) is a CD4 T-cell modulator. Forigerimod TFA is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod TFA can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) .

HY-P5509

C5aR1 antagonist peptide	Peptides	Others
C5aR1 antagonist peptide is a biological active peptide. (This linear peptide is derived from the C-terminus of the chemokine, complement fragment 5 anaphylatoxin (C5a). This peptide functions to inhibit C5a binding and function at human and rat C5a receptors. C5a is crucial to triggering cellular immune responses and its overexpression is involved in arthritis, Alzheimer’s disease, cystic fibrosis, systemic lupus erythematosus, and other immunoinflammatory diseases.)

Cat. No.	Product Name	Target	Research Area

HY-P99267

Rontalizumab RhuMab IFNalpha; Anti-Human IFN alpha Recombinant Antibody	Inhibitory Antibodies	Inflammation/Immunology
Rontalizumab is a humanized IgG1 monoclonal antibody targets IFN-α. Rontalizumab can be used for the research of systemic lupus erythematosus[1].

HY-P99316

Sirukumab CNTO-136	Interleukin Related	Inflammation/Immunology
Sirukumab (CNTO-136) is a human monoclonal anti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab has the potential for active lupus nephritis research .

HY-P99315

Ruplizumab BG 9588; Anti-Human CD40L Recombinant Antibody	TNF Receptor	Inflammation/Immunology
Ruplizumab (BG 9588) is a humanized monoclonal anti-CD40L (TNF Receptor) IgG1κ antibody. Ruplizumab has the potential for systemic lupus erythematosus disease research .

HY-P99219

Sifalimumab MEDI-545; MDX 1103	IFNAR	Inflammation/Immunology
Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research .

HY-P99482

Blisibimod A 623; AMG 623	TNF Receptor	Inflammation/Immunology
Blisibimod (A 623) is a potent and selective tetravalent inhibitor of B-cell activating factor (BAFF). Blisibimod can be used for the research of systemic lupus erythematosus (SLE) .

HY-P9952

Belimumab 2 Publications Verification LymphoStat B	TNF Receptor	Inflammation/Immunology
Belimumab (LymphoStat B) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF). Belimumab can be used for systemic lupus erythematosus (SLE) research .

HY-P99168

Anifrolumab	Inhibitory Antibodies	Inflammation/Immunology
Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research .

HY-P99220

Tabalumab LY2127399	TNF Receptor	Inflammation/Immunology
Tabalumab (LY2127399) is a human anti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus .

HY-P99414

Prezalumab AMG 557	Inhibitory Antibodies	Inflammation/Immunology
Prezalumab (AMG 557) is a humanized IgG2 monoclonal antibody targets ICOSL and BAFF. Prezalumab demonstrates beneficial activities on the arthritis of systemic lupus erythematosus. Prezalumab can be used for the research of sjogren's syndrome cutaneous lupus erythematosus, psoriasis and systemic lupus erythematosus (SLE) .

HY-P99325

Toralizumab IDEC-131; Anti-Human CD40 ligand Recombinant Antibody	TNF Receptor	Inflammation/Immunology
Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab, a immunosuppressive agent, has the potential for active systemic lupus erythematosus (SLE) research .

HY-P99606

Cirevetmab ZTS-00521426	TGF-beta/Smad	Inflammation/Immunology
Cirevetmab (ZTS-00521426) is an immunoglobulin G2-kappa, Canis lupus familiaris TGFB1 caninized monoclonal antibody. Cirevetmab is an immunomodulator .

HY-P9990

Litifilimab BIIB059	Inhibitory Antibodies	Inflammation/Immunology
Litifilimab is a humanized IgG1-κ antibody targeting to C-type lectin domain family 4 member C (CLEC4C). Litifilimab can be used for cutaneous lupus erythematosus (CLE) study .

HY-P99529

Valziflocept BAX1810; TAK-752	Inhibitory Antibodies	Inflammation/Immunology
Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind and neutralize pathogenic IgG, thus forming a "decoy" or "scavenger" receptor that can reduce the severity of autoimmune diseases. Valziflocept can be used in studies of autoimmune diseases such as systemic lupus erythematosus (SLE) .

HY-P99717

Lulizumab pegol BMS-931699	CD28	Inflammation/Immunology
Lulizumab pegol (BMS-931699) is an anti-CD28 antibody antagonist. Lulizumab pegol effectively inhibits T-cell proliferation and it can be used for the reseach of kidney transplantation and autoimmunity disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0214

Prednisone 5+ Cited Publications Dehydrocortisone	Classification of Application Fields Disease Research Fields Endocrinology Cancer	Glucocorticoid Receptor Apoptosis
Prednisone (Adasone) is a corticosteroid agent with anti-inflammatory and immunosuppressive effects that can be used to study diseases related to systemic lupus erythematosus .

HY-N6857

Armepavine	Alkaloids Monophenols other families Classification of Application Fields Source classification Phenols Nelumbo nucifera Gaertn. Plants Isoquinoline Alkaloids Inflammation/Immunology Disease Research Fields Nymphaeaceae	NF-κB
Armepavine, an active compound from Nelumbo nucifera, exerts not only anti-inflammatory effects on human peripheral blood mononuclear cells, but also immunosuppressive effects on T lymphocytes and on lupus nephritic mice. Armepavine inhibits TNF-α-induced MAPK and NF-κB signaling cascades .

Species:	Human (3)
Tag:	His (2) Tag Free (1)
Source:	Sf9 insect cells (1) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P73630A

	SSB Protein, Human lupus La protein; Sjoegren syndrome type B antigen; SS-B	Human	E. coli
	The SSB protein critically binds to the 3' poly(U) terminus of RNA polymerase III transcripts, preventing exonuclease digestion and aiding in correct folding. In coxsackievirus B3 infection, SSB binds to the viral internal ribosome entry site (IRES) and enhances IRES-mediated translation. SSB Protein, Human is the recombinant human-derived SSB protein, expressed by E. coli , with tag free. The total length of SSB Protein, Human is 408 a.a., with molecular weight of ~50 kDa.

HY-P73630

	SSB Protein, Human (His) lupus La protein; Sjoegren syndrome type B antigen; SS-B	Human	E. coli
	SSB Protein crucially binds to the 3' poly(U) terminus of RNA polymerase III transcripts, safeguarding against exonuclease digestion and aiding proper folding. In Coxsackievirus B3 infection, SSB binds to the viral internal ribosome entry site (IRES), enhancing IRES-mediated translation. Interactions with DDX15 and potential interactions with RUFY1 underscore SSB's involvement in diverse cellular processes, emphasizing its multifunctional nature. SSB Protein, Human (His) is the recombinant human-derived SSB protein, expressed by E. coli, with N-His labeled tag. The total length of SSB Protein, Human (His) is 408 a.a., with molecular weight of ~47.8 kDa.

HY-P73629

	SSB Protein, Human (sf9, His) lupus La protein; Sjoegren syndrome type B antigen; SS-B	Human	Sf9 insect cells
	SSB Protein crucially binds to the 3' poly(U) terminus of RNA polymerase III transcripts, safeguarding against exonuclease digestion and aiding proper folding. In Coxsackievirus B3 infection, SSB binds to the viral internal ribosome entry site (IRES), enhancing IRES-mediated translation. Interactions with DDX15 and potential interactions with RUFY1 underscore SSB's involvement in diverse cellular processes, emphasizing its multifunctional nature. SSB Protein, Human (sf9, His) is the recombinant human-derived SSB protein, expressed by Sf9 insect cells, with N-His labeled tag. The total length of SSB Protein, Human (sf9, His) is 408 a.a., with molecular weight of ~49.2 kDa.

Cat. No.	Product Name	Chemical Structure

HY-131968

BMS-986202

BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC₅₀ value of 0.19 nM and a K_i of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC₅₀ value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks